Effect of Ondansetron for Withdrawal Symptoms

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)

NCT00981487

Nausea

COMPLETED PHASE1

Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9)

NCT05657925

Sleep Syncope

NOT_YET_RECRUITING PHASE3

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

NCT01801475

Postoperative Nausea

COMPLETED PHASE1/PHASE2

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

NCT00947128

Nausea Vomiting

COMPLETED PHASE1

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703

Alcohol Use Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Withdrawal Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo - sugar pill

Group Type PLACEBO_COMPARATOR

Ondansetron and Placebo crossover

Intervention Type DRUG

Ondansetron

Group Type EXPERIMENTAL

Ondansetron and Placebo crossover

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ondansetron and Placebo crossover

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No medical contraindications to medication

Exclusion Criteria

* Subjects will be excluded if they have a history of significant psychiatric disorders that would prevent them from engaging in a treatment program.
* Participating in other studies that would interfere with the procedures in this study
* Known or apparent pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No